貴州百靈(002424.SZ):雲南植物藥去年銷售收入已突破10多個億,重慶海扶正申請科創板上市
格隆匯5月6日丨貴州百靈(002424.SZ)於2023年5月5日接受機構調研,問答環節中,就“目前對外參股投資的情況?”,公司回覆稱,一是雲南植物藥,我們持有40%的股權,對應大股東是雲南工投集團。經過4年多努力,去年銷售收入已經突破了10多個億,盈利達到4000多萬。它品種很多,有400多個藥品批文,未來發展潛力大。
二是重慶海扶,目前正在申請科創板上市,是我們目前重點投入的公司。它有自主知識產權的海扶刀超聲治療技術,具有較高的科技水平和市場前景。
三是成都賾靈,是公司參股的新藥研發公司,目前公司是第二大股東。成都賾靈已經擁有了比較良好的股權結構、體制機制與研發團隊,未來成長空間也很大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.